Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of VG161 in Subjects With Advanced Malignant Solid Tumors

NCT04758897 is registered in ClinicalTrials.gov with CNBG-Virogin Biotech (Shanghai) Ltd. as lead sponsor.

NCT NCT04758897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04758897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of VG161 in Subjects With Advanced Malignant Solid Tumors
Lead sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
April 14, 2021
Completion date
December 1, 2022
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid tumor